Corporate finance and biotech are wary of each other.
On one side: predictability, control, traceability. On the other: high risk, long cycles, lumpy spending. Redmontis was designed at that intersection.
Give biotech executives back control of their cash, and the time that comes with it.
A biotech CEO juggles science, funding and a demanding board. Financial steering shouldn't cost them their days or hinge on a spreadsheet only they understand. They need to see their runway at any moment and respond fast, without turning into an analyst.
Generalist financial tools ignore clinical milestones and R&D disbursements. Spreadsheets can't take the load. Redmontis fills that gap with a single, traceable and defensible source of data, shared between the executive and their finance team.
Born in the field, not on a slide.
Redmontis didn't start as a software idea, but as an Excel model built by the founder of Redmontis, used under real-world biotech management conditions and refined over 5 years, board after board, raise after raise. Right where spreadsheets break the moment a trial slips or a grant moves three months out.
Biotech executives and CFOs used it for several months with their own data to improve its responsiveness and relevance before it became a SaaS. They observed its use and value under real-world conditions. Every screen grew out of that use, not from abstract functional logic.
From that battle-tested model, the Redmontis solution was born.
Christophe Hubert
Former biotech CEO, expert in FP&A and financial strategy for biotechs. He lived through the cash decisions that make or break a biotech from the inside, then turned the tool he used into a product.
Become the standard financial infrastructure for biotech.
What the Bloomberg terminal is to capital markets, Redmontis aims to be to biotech financial decision-making.
Precision above all
Defensible, traceable figures that stand up to a board or an auditor.
Designed, not adapted
Built natively for the constraints of biotech, not a generalist tool dressed up.
Institutional restraint
The voice of a senior CFO who knows their subject and doesn't have to sell themselves.
First for the executive, then for their finance team.
- The CEO sees their runway and decides without opening a file
- The CFO or controller works on the same data
- The board reads clear, consistent reporting
- Not an accounting ERP, not a clinical data tool
Let's talk about your financial steering.
Biotech executive or finance lead, let's see how Redmontis fits into your day-to-day.
Contact us